Neuronal expression of familial Alzheimer's disease-mutant human amyloid precursor protein (hAPP) and hAPP-derived amyloid-b (Ab) peptides causes synaptic dysfunction, inflammation and abnormal cerebrovascular tone in transgenic mice. Fatty acids may be involved in these processes, but their contribution to Alzheimer's disease pathogenesis is uncertain. We used a lipidomics approach to generate a broad profile of fatty acids in brain tissues of hAPP-expressing mice and found an increase in arachidonic acid and its metabolites, suggesting increased activity of the group IV isoform of phospholipase A 2 (GIVA-PLA 2 ). The levels of activated GIVA-PLA 2 in the hippocampus were increased in individuals with Alzheimer's disease and in hAPP mice. Ab caused a dose-dependent increase in GIVA-PLA 2 phosphorylation in neuronal cultures. Inhibition of GIVA-PLA 2 diminished Ab-induced neurotoxicity. Genetic ablation or reduction of GIVA-PLA 2 protected hAPP mice against Ab-dependent deficits in learning and memory, behavioral alterations and premature mortality. Inhibition of GIVA-PLA 2 may be beneficial in the treatment and prevention of Alzheimer's disease.
First described a century ago, Alzheimer's disease has increased markedly in prevalence and no effective treatments exist 1 . Transgenic mice with neuronal expression of familial Alzheimer's disease-mutant hAPP show age-dependent deficits in learning and memory, behavioral alterations, and premature mortality 2, 3 . Ab peptides, released from hAPP by proteolysis, are thought to mediate these deficits, but the exact mechanisms remain to be fully elucidated 1, 3 .
Essential fatty acids and their metabolites ( Supplementary Fig. 1 online) participate in processes involved in the pathogenesis of Alzheimer's disease, including synaptic plasticity 4 , inflammation, cerebrovascular function 5, 6 and oxidative stress 7 . Fatty acids are rapidly taken up by the brain, incorporated into phospholipids and released by phospholipase A 2 (PLA 2 ) 8 . Changing the dietary intake of essential fatty acids modulates the phenotype of hAPP mice 9 and may affect cognition and Alzheimer's disease progression in humans 10 .
However, fatty acid metabolism in Alzheimer's disease patients and hAPP mice has not yet been broadly profiled. Therefore, we used an unbiased lipidomics approach 11 to examine PLA 2 -dependent fatty acid metabolism in brain tissues of hAPP mice. Our lipidomics profile led us to hypothesize that a specific isoform of PLA 2 contributes to Abmediated neuronal deficits. We tested this hypothesis by perturbation analyses in vitro and in vivo.
RESULTS

Increased fatty acids in hAPP mice
To profile essential fatty acid metabolism, we measured the amounts of 44 pertinent metabolites present in the hippocampus and cortex of transgenic mice with neuronal expression of familial Alzheimer's disease-mutant hAPP (line J20, refs. 2,12-15) and nontransgenic (NTG) controls by simultaneous liquid chromatography-tandem triple-quadrupole mass spectrometry (LC-MS/MS) ( Supplementary  Fig. 1 ). Hippocampal levels of arachidonic acid were higher in hAPP mice than in NTG controls, whereas cortical arachidonic acid levels were comparable ( Fig. 1a) . Total arachidonic acid-derived metabolites were also increased in the hippocampus, but not cortex, of hAPP mice (Fig. 1b) . Hippocampal, but not cortical, levels of prostaglandin E 2 and B 2 (PGE 2 and PGB 2 , respectively) were higher in hAPP mice than in NTG mice (Fig. 1c) . The increase in PGE 2 is consistent with the increase in hippocampal cyclooxygenase-2 found in another hAPP transgenic model 16 . Both arachidonic acid and prostaglandin regulate long-term potentiation 17 , which is important for learning and memory. Excessive levels of arachidonic acid and prostaglandin can contribute to excitotoxicity 5 , which may be involved in Alzheimer's disease pathogenesis 3, 12, 13 . In addition, arachidonic acid and prostaglandin contribute to inflammation, which may also contribute to Alzheimer's disease 1 .
Inflammation might be further promoted by leukotrienes, arachidonic acid-derived fatty acids that are potent chemoattractants for monocytes and granulocytes 18 . Leukotriene B 4 (LTB 4 ) levels were higher in hAPP mice than in NTG controls in both the hippocampus and cortex ( Fig. 1d) . Increased LTB 4 levels may contribute to the microgliosis seen in hAPP mice and individuals with Alzheimer's disease.
Arachidonic acid, PGD 2 , PGB 2 and LTB 4 levels were not altered in wild-type hAPP transgenic mice from line I5 ( Supplementary Fig. 2 online), which have comparable hAPP levels to those in hAPP-J20 mice, but much lower Ab levels 14 .
Neurovascular coupling also appears to be affected in Alzheimer's disease 19 , possibly because the vasoconstrictive effects of Ab alter the normal vascular dilation in response to increased neuronal activity 20 . This effect may be counteracted by prostaglandin and epoxyeicosatrienoic acids (EETs); the latter are derived from arachidonic acid through the activity of cytochrome p450 monooxygenase in astrocytes surrounding blood vessels 5, 6 . PGE 2 and EETs cause cerebrovascular dilation in response to neuronal activity 5, 6 . The four regioisomers of EETs have similar biological activities and can be metabolized into less active dihydroxyeicosatrienoic acids (DHET), which can serve as markers of EET production 6 . Cortical levels of 14,15-EET, 14,15-DHET and 8,9-DHET were higher in hAPP mice than in NTG controls ( Fig. 1e and Supplementary Fig. 2 ). hAPP mice also showed a trend toward increased cortical and hippocampal levels of other EET metabolites ( Supplementary Fig. 3 online) .
In NTG mice, fatty acid levels were also higher in the hippocampus than in the cortex ( Fig. 1f ), suggesting that PLA 2 activity is slightly higher in the hippocampus. The lipidomics profile did not demonstrate significant differences between hAPP and NTG mice in the levels of other fatty acids liberated directly by PLA 2 (docosahexaenoic, eicosapentaenoic, linoleic acid and a-linolenic acid, P 4 0.05; Supplementary Fig. 4 online) . Except for 12-hydroxyeicosapentaenoic acid (HEPE), whose hippocampal levels were higher in hAPP mice than in NTG controls (Po 0.05), we also found no significant differences in other prostaglandins, hydroxyeicosatetraenoic acids or more distal metabolites (P 4 0.05; Supplementary Figs. 4, 5 and 6 online).
Thus, the lipidomics profile revealed a rather selective alteration in PLA 2 -dependent fatty acid metabolism in hAPP mice, consisting primarily of increased levels of arachidonic acid and its metabolites. Because different isoforms of PLA 2 have specificities for particular fatty acids 8 , this fatty acid profile implicates a specific isoform of PLA 2 .
Group IVA-PLA 2 is present in mouse neurons Three isoforms of PLA 2 have been reported in the brain (Groups II, IVA and VIA). GIVA-PLA 2 has the strongest preference for arachidonic acid, is regulated by Ca 2+ and has phosphorylation sites for kinases implicated in Alzheimer's disease 8 . GIVA-PLA 2 -deficient mice fail to generate arachidonic acid metabolites after brain injury 8, 21 . In contrast, GVIA-PLA 2 is not responsive to Ca 2+ and lacks phosphorylation sites for kinases that are implicated in Alzheimer's disease 8 . The GIIA isoform is absent in our hAPP and NTG mice because of an inbred gene deletion in the C57BL/6 strain 21 . These data suggested that GIVA-PLA 2 may cause the increased arachidonic acid metabolism in hAPP mice. However, in a previous study, no GIVA-PLA 2 immunoreactivity was detected in the brains of NTG and hAPP mice 22 , and analysis of GIVA-PLA 2 in Alzheimer's disease has yielded inconsistent results 23, 24 .
GIVA-PLA 2 immunoreactivity was readily detectable in the brains of our hAPP mice and NTG controls. Immunostaining with an antibody specific for GIVA-PLA 2 resulted in comparable widespread neuronal labeling in brain sections from NTG and hAPP mice on the wild-type GIVA-PLA 2 background ( Fig. 2a,b ), but not the GIVA-PLA2-deficient background ( Fig. 2c ). Dense labeling of granule cells of the dentate gyrus and pyramidal neurons in the CA1-3 regions was seen in hAPP and NTG mice ( Fig. 2d,e ), but not in GIVA-PLA2-deficient mice ( Fig. 2f ). Our findings are consistent with detection of neuronal GIVA-PLA 2 mRNA 25 and immunoreactivity 26 in rats.
GIVA-PLA 2 activation in hAPP hippocampus
Next, we determined whether phosphorylated, putatively active GIVA-PLA 2 was increased in the brains of hAPP mice. Phosphorylated and unphosphorylated forms of GIVA-PLA 2 can be detected with the same antibody because phosphorylation leads to an electrophoretic mobility shift. Hippocampal, but not cortical, levels of phosphorylated GIVA-PLA 2 were higher in hAPP mice than in NTG controls ( Fig. 2g-i) , which is consistent with the differences in fatty acid levels in these regions ( Fig. 1f) . No GIVA-PLA 2 band was seen in brains from GIVA-PLA 2 -deficient mice ( Fig. 2g) .
To determine whether the region-specific increase in GIVA-PLA 2 phosphorylation was related to differences in the levels of hAPP transgene products, we measured hAPP mRNA by quantitative reverse transcriptase PCR (RT-PCR) and Ab by ELISA in 2-4-month-old hAPP mice (before plaque formation). The levels of hAPP mRNA ( Fig. 2j) , Ab 1-x ( Fig. 2k) and Ab (Fig. 2l ) present were indeed higher in hippocampus than in cortex in hAPP mice.
Because fresh tissue for reliable lipidomics analysis in human Alzheimer's disease patients is not readily available and phosphorylated GIVA-PLA 2 levels correlate with arachidonic acid production 8 , we measured hippocampal levels of phosphorylated GIVA-PLA 2 in human postmortem tissues. Compared with non-demented controls, phosphorylated GIVA-PLA 2 levels were elevated in Alzheimer's disease patients, but not in patients with frontotemporal dementia ( Fig. 2m-n and Supplementary Fig. 7 online), who do not have elevated Ab levels. 
GIVA-PLA 2 contributes to Ab-induced neurotoxicity
To determine whether exposure to extracellular Ab was sufficient to activate neuronal GIVA-PLA 2 , we assessed the effect of synthetic Ab 1-42 oligomers on GIVA-PLA 2 phosphorylation in primary neuronal cultures. Treatment with Ab 1-42 peptide, but not Ab 42-1 control peptide, caused a dose-and time-dependent increase in phosphorylated GIVA-PLA 2 (Fig. 3a) . Treatment with cell-secreted hAPP had no such effect ( Supplementary Fig. 8 online) . Similarly, arachidonic acid release was increased by Ab 1-42 , but not by Ab 42-1 or cell-secreted hAPP ( Supplementary Fig. 8 ). Ab 1--42 -induced phosphorylation of GIVA-PLA 2 was blocked by the broad-spectrum MAPK inhibitor PD98059 and by the MEK inhibitor SB203580 ( Supplementary  Fig. 8 ), suggesting mediator roles for these kinases. cultures with the Ca 2+ chelators EGTA and BAPTA, inhibitors of MAPK or MEK, or the GIVA-PLA 2 inhibitor arachidonyl trifluoromethyl ketone (AA-COCF 3 ) 5 , but not by pretreatment with the GVIA-PLA 2 inhibitor bromoenolactone (BEL) ( Supplementary Fig. 8 ). Ab 1-42 and arachidonic acid each caused a dose-dependent decrease in neuronal viability (Fig. 3b,c) , consistent with previous findings 3, 27 . Because a nonspecific PLA 2 inhibitor protected neurons against Ab toxicity 28 , we wondered whether this effect is the result of specific inhibition of GIVA-PLA 2 . Pretreatment of neuronal cultures with AA-COCF 3 reduced Ab 1-42 -induced cell death, whereas BEL had no effect ( Fig. 3d and Supplementary Fig. 8 ).
How might GIVA-PLA 2 activation contribute to Ab-induced neuronal toxicity? This toxicity is caused, at least partly, by overexcitation 3, 29 . Oligomeric Ab generates rapid inward currents in neurons that appear to be necessary for subsequent neuronal toxicity [29] [30] [31] . Oligomeric Ab-induced neurotoxicity involves AMPA receptors (AMPARs) 32 , and AMPAR antagonists can block acute Ab-induced neuronal activation and neurotoxicity 31, 33 . AMPAR currents are dependent on the number of surface AMPARs 32, 34 . PLA 2 activity leads to phosphorylation of AMPARs in a manner that would predict an increase in their surface levels 4 , consistent with the ability of GIVA-PLA 2 and arachidonic acid to cause neuronal excitation 35 and increase AMPAR activity 36 . Moreover, controlling for neuronal cell loss, the levels of AMPAR and of AMPAR binding in the hippocampus were higher in individuals with Alzheimer's disease than in controls, particularly in the molecular layer of the dentate gyrus 37 . We therefore hypothesized that GIVA-PLA 2 contributes to Ab-induced neuronal toxicity by increasing the amount of AMPAR in the surface. Ab 1-42 and arachidonic acid each increased surface levels of the AMPAR subunits GluR1 (Fig. 3e) and GluR2 ( Supplementary Fig. 9 online) in cultured neurons within 10 min. Inhibition of GIVA-PLA 2 blocked this Ab 1-42 -induced increase in GluR1 ( Fig. 3e) and GluR2 ( Supplementary Fig. 9 ). The Ab-induced increase in surface AMPAR subunits was transient, as surface levels returned to baseline ( Fig. 3f and Supplementary Fig. 9 ) and then decreased below baseline levels (data not shown) with continued exposure to Ab, consistent with previous reports 30, 32, 38, 39 . To determine whether the early Ab 1-42 -induced increase in AMPAR contributed to subsequent neuronal death, we pretreated cells with the AMPAR blocker 2,3-dihydroxy-6-nitro-7sulfamoyl-benzo[f]quinoxaline-2,3-dione (NBQX). AMPAR blockade significantly decreased neuronal toxicity induced by Ab 1-42 or arachidonic acid (P o 0.0001; Supplementary Fig. 8 ). Consistent with the Ab 1-42 -and GIVA-PLA 2 -dependent increase in the amount of surface AMPAR, treatment of brain slices of NTG wild-type mice with oligomeric Ab 1-42 or arachidonic acid caused an immediate increase in neuronal activity ( Supplementary Fig. 10 online) . Pretreatment of slices with a GIVA-PLA 2 inhibitor blocked this Ab 1-42 effect (Supplementary Fig. 10 ).
GIVA-PLA 2 reduction improves memory in hAPP mice
To determine whether GIVA-PLA 2 contributes to Ab-dependent behavioral deficits in vivo, we bred hAPP and NTG mice with GIVA-PLA 2deficient mice to generate six genotypes, APP/Pla2g4a +/+ , APP/ Pla2g4a +/-, APP/Pla2g4a -/-, Pla2g4a +/+ , Pla2g4a +/and Pla2g4a -/-. These groups did not differ in background strain, body weight, gross motor function or swim speed ( Supplementary Fig. 11 online) . Removal or reduction of GIVA-PLA 2 significantly reduced hippocampal levels of arachidonic acid and its metabolites in hAPP mice (P o 0.001 and P o 0.0001 for Pla2g4a +/À and Pla2g4a À/À mice, respectively; Supplementary Fig. 12 online) . To determine whether these changes ameliorated cognitive deficits in hAPP mice, we tested the above groups in the Morris water maze. In the cued component of this test, hAPP mice showed deficits in task acquisition that were independent of GIVA-PLA 2 levels (Fig. 4a) . In the hidden platform (spatial) component of the test, complete or partial removal of GIVA-PLA 2 reduced learning deficits in hAPP mice (Fig. 4b) . In the probe trial, a putative measure of spatial learning and memory retention, only APP/Pla2g4a +/+ mice failed to favor the target platform location (Fig. 4c,d) . Removal or reduction of GIVA-PLA 2 significantly improved target crossings in hAPP mice in the probe trial (P o 0.01 and P o 0.05, respectively; Fig. 4c,d) . In addition, hAPP mice with GIVA-PLA 2 reduction or removal showed a trend for improved overall target quadrant preference during the final probe trial (data not shown).
Deficits in learning and memory in hAPP mice may involve aberrant excitatory and inhibitory network activity 3, 13 and correlate well with depletions of Ca 2+ -regulated, synaptic activity-dependent proteins in the dentate gyrus 2 . Removal of GIVA-PLA 2 prevented depletion of the Ca 2+ -binding protein calbindin in hAPP mice ( Supplementary Fig. 13 online). Together, these results suggest a causal role for GIVA-PLA 2 in Ab-dependent impairments of learning and memory.
Other behavioral abnormalities and premature mortality hAPP mice demonstrate hyperactivity that may be related to memory deficits and entorhinal cortex dysfunction 14, 15 . Complete or partial removal of GIVA-PLA 2 significantly decreased hyperactivity in hAPP mice, as reflected in the open field test (P o 0.001; Fig. 5a,b ) and the Y maze (P o 0.05 and P o 0.0001; Fig. 5c,d ). hAPP mice also show a disinhibition-like phenotype in the elevated plus maze, which is widely used to assess anxiety and exploratory behavior 14, 15 . Both PLA 2 and hAPP genotype significantly affected elevated plus maze performance (APP effect, P o 0.0001 for time spent and distance traveled in the open arms and for edge pokes; Pla2g4a effect, P o 0.05 for time spent and distance traveled in the open arms, P o 0.01 for edge pokes; Fig. 5e-g) . Reduction of GIVA-PLA 2 dose-dependently diminished the time spent ( Fig. 5e ) and distance traveled (Fig. 5f) in the open arms of the maze and the number of edge pokes (Fig. 5g) in hAPP mice. In mice without hAPP, removal of GIVA-PLA 2 had much more subtle or no effects on these behaviors ( Fig. 5a-g) . hAPP mice also exhibited premature mortality (Fig. 5h) , possibly related to their lowered seizure threshold 12, 13, 15 . Removal or reduction of GIVA-PLA 2 significantly improved the survival of hAPP mice (P o 0.001; Fig. 5h ) without altering the levels of hAPP (Fig. 6a) , Ab 1-x ( Fig. 6b) , Ab 1-42 (Fig. 6c) or the Ab 1-42 /Ab 1-x ratio (Fig. 6d) . Removal or reduction of GIVA-PLA 2 also did not alter Ab deposition, astroglial activation (GFAP immunostaining) or microglial numbers (Iba-1 immunostaining) (data not shown). These findings suggest that GIVA-PLA 2 reduction blocks or counteracts Alzheimer's diseaserelated abnormalities downstream of Ab production and deposition.
DISCUSSION
Our study shows that reduction of GIVA-PLA 2 can prevent diverse Ab-dependent functional impairments in a transgenic mouse model of Alzheimer's disease. We focused on this enzyme because our unbiased lipidomics analysis revealed a selective increase in arachidonic acid and its metabolites in the brain tissues of hAPP mice, suggesting increased activity of this particular PLA 2 isoform. We also found that GIVA-PLA 2 was expressed in the brains of mice and that hAPP mice and individuals with Alzheimer's disease have increased levels of phosphorylated (putatively activated) GIVA-PLA 2 in the hippocampus, which is particularly vulnerable to Alzheimer's disease in humans and to Ab-induced neuronal deficits in transgenic mice 2,3,12-15 . Because PLA 2 releases fatty acids from phospholipids 8 , the increased GIVA-PLA 2 activity that we detected in hAPP mice is consistent with the decreased levels of phospholipid-bound arachidonic acid in Alzheimer's disease brains 40 , further underlining the potential relevance of our findings to the human condition. Increased GIVA-PLA 2 activity in hAPP mice may also be related to the increases in isoprostanes (nonenzymatic arachidonic acid metabolites that form during oxidative stress) in the brain and cerebrospinal fluid (CSF) of individuals with Alzheimer's disease and hAPP mice 7 and in 4-hydroxynonenals (oxidative aldehyde products of arachidonic acid) in the brains of Alzheimer's disease patients 41, 42 .
Notably, the translocation of GIVA-PLA 2 to its phospholipid substrate is primarily regulated by intracellular calcium 8 , and several lines of evidence suggest that Ca 2+ -dependent signaling pathways are dysregulated in the neurons of hAPP mice, particularly in the hippocampus 1-3,12-15 . Because transgene expression and Ab levels were higher in the hippocampus than the cortex, the regional differences in aberrant GIVA-PLA 2 activation may primarily reflect differences in Ab levels and a threshold effect. Consistent with this interpretation, our in vitro studies demonstrated dose-dependent neuronal GIVA-PLA 2 activation by extracellular Ab .
The concentration of any fatty acid product is dependent on the concentration of its precursor substrate and the enzymatic activity of the protein that metabolizes that precursor. Elevated levels of LTB 4 and 14,15-EET in the cortex when arachidonic acid levels are normal suggest that the activities of 5-LO, p450, LTA 4 hydrolase and soluble epoxide hydrolase may be increased in the cortex of hAPP-J20 mice compared with NTG mice.
Several lines of evidence suggest that GIVA-PLA 2 activation contributes to Ab 1-42 -dependent neurotoxicity, which can range from synaptic dysfunction to neuronal cell death. Ab-induced neurotoxicity requires AMPAR activity, which is regulated by surface AMPAR levels 31, 32, 43 . Ab 1-42 acutely elevated surface AMPAR levels in cultured neurons and inhibition of GIVA-PLA 2 blocked this process. Treatment with arachidonic acid also increased surface AMPAR levels. Thus, GIVA-PLA 2 and arachidonic acid may contribute to Ab neurotoxicity by mediating Ab-induced increases in surface AMPAR expression ( Supplementary Fig. 14 online) . Indeed, increased surface levels of AMPARs would be expected to increase neuronal excitability 44 . Early neuronal excitability is thought to mediate acute Ab 1-42 toxicity 29 and to be essential for delayed Ab 1-42 -dependent synaptic deficits 30 .
In vivo and in vitro evidence suggests that Ab can elicit not only neuronal overexcitation, but also synaptic depression, and that both of these mechanisms may contribute to Alzheimer's disease-related cognitive impairments 3, 12, 13, 30, 32, 45 . Our results raise the possibility that the decreases in surface AMPARs observed after longer exposure to Ab 32,39 may result from feedback inhibition (for example, synaptic scaling 46 ) triggered by the acute increase in surface AMPAR expression and associated increases in neuronal excitability ( Supplementary  Fig. 14) . Additional potential causes include long-term depressionlike mechanisms 32, 39, 43 and impairments of neuronal functions.
It is difficult to extrapolate from in vitro to in vivo conditions, and activation of GIVA-PLA 2 leads to the production of many fatty acids with diverse biological activities 8, 18 . Thus, it was not clear a priori whether GIVA-PLA 2 activation in hAPP mice or Alzheimer's disease was beneficial or detrimental. For instance, arachidonic acid and its metabolites participate in synaptic plasticity 4 , excitotoxicity 47 , cerebrovascular regulation 5,6 , oxidative stress 7,41,42 and inflammation 5 , all of which have been implicated in the pathogenesis of Alzheimer's disease 1, 3, 5 .
To determine whether a reduction in GIVA-PLA 2 activity is beneficial or detrimental in the presence of abnormally elevated Ab levels, we crossed hAPP mice onto a GIVA-PLA 2 -deficient background. Elimination or partial reduction of GIVA-PLA 2 was well tolerated and effectively reduced learning and memory deficits, behavioral alterations, and premature mortality in hAPP mice. Our results suggest that GIVA-PLA 2 contributes to the pathogenesis of these abnormalities and might be a useful target for therapeutic interventions in Alzheimer's disease.
METHODS
Mice and tissue. We analyzed sex-balanced groups of 2-6-month-old heterozygous transgenic and NTG mice from line J20 (ref. 2, [12] [13] [14] [15] . Pla2g4a -/mice were generated by J. Bonventre (Harvard Medical School) 21 . All mice were on a C57/BL6 background. All experiments were approved by the Institutional Animal Care and Use Committee of the University of California, San Francisco. Anesthetized mice were killed by perfusion transcardially with saline. Mouse brains were processed for immunohistochemistry 12 , protein 12 and lipid analysis 11, 48 as described.
Lipid analysis. Frozen brain regions were pulverized in liquid nitrogen and spiked with deuterated and odd-chain metabolite surrogates 48 before homogenization in ice-cold methanol. Samples were diluted to 10% methanol with phosphate-buffered saline (pH7.4) and lipids were isolated by solid-phase extraction on Oasis HLB cartridges (Waters). Residues were dried under vacuum and reconstituted in the presence of internal standards allowing surrogate recoveries to be determined 48 . Analytes were separated by reverse-phase liquid chromatography on a Waters UPLC equipped with a 2.1-Â 150-mm, 1.7-mm C18-BEH Acquity column. A gradient of mobile phases A (water/0.1% acetic acid, wt/wt) and B (80:15 acetonitrile to methanol/ 0.1% acetic acid (wt/wt), vol/vol) was used. Analytes were detected by negativemode electrospray ionization with a tandem quadrupole mass spectrometer (QuattroMicro, Waters) operated in multi-reaction monitoring mode and quantified against five-point calibration curves bracketing the observed concentrations. Quantitative analyte measurements were adjusted according to the recovery of structurally similar surrogate metabolites that were spiked into the samples before lipid extraction. Less than 2% of the spiked epoxide and hydroxyprostane rings were lost during sample preparation. The dehydration products of PGE 2 and PGD 2 (that is, PGB 2 and PGJ 2 ) were quantified and combined with their parent prostaglandins before statistical analysis.
Primary neuronal culture. Rat cortices (embryonic day 18) were digested with papain. Cells were plated in polylysine-coated wells and maintained in serumfree neurobasal medium supplemented with B27 and antibiotics. Half the medium was changed after 7 d in culture and 1 d before use. Cells were used after 14 d in culture. More than 95% of the cells were neurons, as determined by staining with antibody for the neuron-specific marker NeuN (data not shown). Cell viability was assessed with trypan blue 49 . Neuronal cell treatments included Ab 1-42 , arachidonic acid, AA-COCF 3 , BEL (Cayman Chemical), cell-secreted hAPP 695 obtained from medium of Lipofectamine-transfected HEK cells, NBQX, PD98059 and SB203580 (Sigma).
Ab preparation. To prepare Ab peptides, we solubilized 1 mg of Ab (Biopeptide) in a glass tube with ice-cooled 1,1,1,3,3,3-hexafluoro-2-propanol (Sigma), incubated it for 1 h at 19-22 1C, allowed it to evaporate over 24 h and spun it for 10 min on a speed vacuum at maximal force of 300g. The remaining precipitate was solubilized with 100 mM DMSO in neurobasal medium, incubated at 4 1C for 48 h and centrifuged at 14,000g for 10 min at 4 1C. Soluble oligomers were collected and resuspended in neurobasal medium. Concentrations of monomeric Ab were determined by absorbance at 595 nm after addition of Coomassie reagent (Sigma).
Quantitative RT-PCR. Reverse transcriptase reactions contained 300 ng of total RNA (DNase treated) and random hexamer plus oligo d(T) primers. Diluted reactions were analyzed with SYBR green PCR reagents and an ABI Prism 7700 (Applied Biosystems). cDNA levels of hAPP and mGAPDH were determined relative to standard curves from pooled samples. The slope of standard curves, control reactions without reverse transcriptase and dissociation curves of products indicated adequate PCR quality. For hAPP primers, we used 5¢-GAG GAG GAT GAC TCG GAT GTC T-3¢ (hAPP 5RF primer sequence) and 5¢-AGC CAC TTC TTC CTC CTC TGC TA-3¢ (hAPP 6RR primer sequence).
Ab ELISAs. Snap-frozen brain tissues were homogenized with guanidine buffer followed by ELISA measurements of human Ab peptides 15 . The ELISA for Ab 1-42 detects this specific peptide. The ELISA for Ab 1-x recognizes N-terminal fragments of Ab containing the first 28 amino acids.
Immunoblotting. Frozen samples were homogenized in lysis buffer (50 mM Tris-HCl, 150 mM NaCl, protease inhibitor cocktail (Roche), 10 mM pepstatin, 5 mM EDTA, 400 mM PMSF and 0.2% Triton X-100, vol/vol), sonicated on ice and centrifuged (5,000g, 15 min). Protein concentration was determined by Bradford protein assay. Protein (40 mg) was loaded into each well of a 4-12% gradient SDS-PAGE gel. Gels were transferred to nitrocellulose membranes. Membranes were incubated with rabbit antibody to GIVA-PLA 2 (1:200, Santa Cruz Biotechnology), rabbit antibody to phospho-GIVA-PLA 2 (1:200, Abd Serotec) or rabbit antibody to calbindin (1:1,000, Swant) in blocking buffer for 1 h. For secondary antibodies, we used goat anti-rabbit antibodies (Chemicon) at a 1:10,000 dilution. Protein bands were visualized with an ECL system (Pierce) and quantified densitometrically with Image J (US National Institutes of Health) software.
Immunohistochemistry. Sections were stained for GIVA-PLA 2 , Ab and GFAP with an avidin-biotin/peroxidase system (Vector Laboratories). For antigen retrieval, sections were boiled in 50 mM citric acid for 15 min. Endogenous peroxidase activity was blocked with 3% hydrogen peroxide in methanol (vol/vol) for 15 min. Sections were blocked at 19-22 1C for 1 h in 10% serum and 1% nonfat milk (wt/vol), and incubated overnight with a rabbit antibody to GIVA-PLA 2 (N-216, 1:100; Santa Cruz Biotechnology), mouse antibody to Ab 1-5 (1:500, 3D6 antibody, Elan Pharmaceuticals) or rabbit antibody to GFAP (1:500, Dako) at 4 1C in blocking solution. Secondary biotinylated antibody was used at a dilution of 1:200 (Vector Laboratories). The chromagen was diaminobenzidine.
Biotinylation assay for AMPAR. Primary neuronal cultures were treated with Ab or arachidonic acid in artificial CSF (aCSF) or with vehicle for 10, 30 or 60 min and rinsed with ice-cold aCSF, and surface receptors were bound with EZ-link sulfo-NHS-SS-biotin (Pierce). After rinsing with ice-cold glycine and then with ice-cold aCSF, cells were treated with immunoblotting lysis buffer (above) and scraped from the 24-well plate. Surface receptors were precipitated with avidin-Sepharose beads (Pierce). Samples from two wells were combined for western blot analysis with antibodies against GluR1 (1:1,000, Chemicon) or GluR2 (1:1,000, Chemicon) 50 .
Behavioral testing. To minimize the effects of social and environmental stressors on behavior, we housed mice singly under conditions of controlled temperature with a standard 12-h light/12-h dark cycle. Before each behavioral assessment of mice in the elevated plus maze, open field and Y maze tests, residues were removed and the apparatus was cleaned with ethanol wipes to standardize odors.
Water-maze test. As described previously 2, 12 , mice were trained to locate first a visible platform (days 1-3) and then a hidden platform (days 4-8) in a pool (122-cm diameter) filled with opaque water (18 1C) . Training consisted of two daily sessions 2-3 h apart, with each consisting of two (visible) or three (hidden) 60-s trials. During hidden platform training, the platform location was kept constant (in the center of the target quadrant) and the starting point was changed between trials. For all trials, the time (latency) and path length to reach the platform and the swim speed were recorded with a Noldus Instruments EthoVision video tracking system (Noldus Information Technology). On days 6, 9 and 11 (before the first trial of the day), the platform was removed for a 60-s probe trial, during which the proportion of time spent in the different quadrants and the number of target crossings were recorded. Mice that demonstrated a thigmotactic swim pattern during training were excluded from analysis (0-2 mice per genotype).
Open field activity. To assess activity levels, we placed mice individually into well-lit automated activity cages with rows of infrared photocells on each side interfaced with a computer (San Diego Instruments). Open field activity was recorded for two consecutive 5-min periods. Beam breaks were recorded automatically and used to calculate total fine and ambulatory movements, path lengths, and the number of rearings at the center and periphery of the field. Y maze. Exploratory behavior was tested in a Y-shaped maze consisting of three identical arms, made of dark opaque polyvinyl plastic, with equal angles between each arm. For each trial, mice were placed individually into one arm and allowed to explore the maze for 6 min, during which the sequence and number of arm entries were recorded manually.
Elevated plus maze. Exploratory behavior and anxiety were assessed with an elevated, plus-shaped maze consisting of two open arms and two closed arms equipped with rows of infrared photocells interfaced with a computer (Hamilton-Kinder). Briefly, mice were placed individually in the center of the maze and allowed to explore freely for 10 min. Beam breaks were recorded automatically and used to calculate the number of entries, distance traveled, the total time spent in each arm and the number of extensions over the edges of the open arms (edge pokes).
Slice preparation and electrophysiology. We used 4-month-old C57/BL6J mice (n ¼ 4) for in vitro recordings. Mice were deeply anesthetized and decapitated. The brain was rapidly removed and placed in cold (B4 1C) oxygenated slicing solution containing 2.5 mM KCl, 1.25 mM NaH 2 PO 4 , 10 mM MgSO 4 , 0.5 mM CaCl 2 , 26 mM NaHCO 3 , 11 mM glucose and 234 mM sucrose. A block of brain was fastened to the stage of a Vibratome 3000 (Vibratome) with cyanoacrylate and 350-mm coronal slices were cut in slicing solution. Slices were incubated for Z30 min at 30 1C in standard aCSF containing 2.5 mM KCl, 126 mM NaCl, 10 mM glucose, 1.25 mM NaH 2 PO 4 , 1 mM MgSO 4 , 2 mM CaCl 2 and 26 mM NaHCO 3 (pH B7.4 when gassed with a mixture of 95% O 2 / 5% CO 2 ). Single slices were transferred to a submerged recording chamber where they were maintained at 30 1C and perfused at a rate of B2 ml min -1 . Recordings were made from neurons identified under infrared differential interference contrast video microscopy with a Zeiss Axioskop 2 FS plus microscope. Patch pipettes (4-6 MO) were pulled from borosilicate glass World Precision Instrument and filled with 5 mM KCl, 135 mM potassium gluconate, 2 mM NaCl, 10 mM HEPES, 4 mM EGTA, 4 mM MgATP and 0.3 mM Na 3 GTP (pH B7.3, 287 mosmol). Access resistance (R A ) was monitored during recordings and neurons were discarded if R A 4 15 MO. Drugs were applied locally via a local perfusion system (Automate Scientific).
Data analysis. For western blots, protein levels were normalized to mean levels in NTG controls. Unpaired, two-tailed t tests were used to assess differences between means for LC-MS/MS and western blot analyses and the effect of AA-COCF 3 on cell viability. We used two-way ANOVA for western blot analysis of GIVA-PLA 2 after Ab treatments and one-way ANOVA with repeated measures for experiments assessing the dose-and time-dependent effects of Ab and arachidonic acid on cell viability. Behavioral data were assessed by two-way ANOVA with repeated measures where indicated. Tukey or Dunnett post hoc tests were used for multiple comparisons. Null hypotheses were rejected at the 0.05 level.
Note: Supplementary information is available on the Nature Neuroscience website.
